Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, announced an achievement in converting glucoraphanin into sulforaphane, an active ingredient in broccoli extract.
BON's dedicated R&D team has conducted extensive research, and completed the design of a new compound system, that, when introduced into the human body, integrates enzymes with broccoli extract, efficiently catalyzing glucoraphanin, a precursor, into sulforaphane. This technological advancement not only boosts the transformation rate and bioavailability of broccoli extract, but also reduces costs significantly, allowing for rapid market expansion. Additionally, it extends the shelf life of extract products, providing convenience to customers.
Based on this new design, BON plans to launch a series of new health supplement products under the registered trademark: Broclife in areas of sleep improvement, digestive health, and immune health, seeking to meet the market demand for natural health products.
Recognized for its numerous health benefits such as antioxidant, anti-aging, anti-inflammatory effects, immune enhancement, inhibition of cancer cell replication, support for digestive health, and promotion of the central nervous system, broccoli extract is a highly valuable ingredient. However, its application has been limited due to challenges related to formulation effectiveness and the high costs involved in production.
Yongwei Hu, CEO & Chairman of BON, stated, "We believe that our new Broclife products will address the challenges related to both effectiveness and costs in broccoli extract products, and play a crucial role in the global health market. With this innovation, BON hopes to unleash substantial growth with the hope to reach a projected of market of tens of millions of dollars over the next three years. This achievement will not only drive the Company's expansion but also deliver exceptional performance and value to our shareholders."